Literature DB >> 16221867

Renal apolipoprotein A-I amyloidosis: a rare and usually ignored cause of hereditary tubulointerstitial nephritis.

Gina Gregorini1, Claudia Izzi, Laura Obici, Regina Tardanico, Christoph Röcken, Battista Fabio Viola, Mariano Capistrano, Simona Donadei, Luciano Biasi, Tiziano Scalvini, Giampaolo Merlini, Francesco Scolari.   

Abstract

Apolipoprotein A-I amyloidosis is a rare, late-onset, autosomal dominant condition characterized by systemic deposition of amyloid in tissues, the major clinical problems being related to renal, hepatic, and cardiac involvement. Described is the clinical and histologic picture of renal involvement as a result of apolipoprotein A-I amyloidosis in five families of Italian ancestry. In all of the affected family members, the disease was caused by the Leu75Pro heterozygous mutation in exon 4 of apolipoprotein A-I gene, as demonstrated by direct sequencing and RFLP analysis. Immunohistochemistry confirmed that amyloid deposits were specifically stained with an anti-apolipoprotein A-I antibody. The clinical phenotype was mainly characterized by a variable combination of kidney and liver disturbance. The occurrence of renal involvement seemed to be almost universal, although its severity varied greatly ranging from subclinical organ damage to overt, slowly progressive renal dysfunction. The renal presentation was consistent with a tubulointerstitial disease, as suggested by the findings of defective urine-concentrating capacity, moderate polyuria, negative urinalysis, and mild tubular proteinuria. Histology confirmed tubulointerstitial nephritis. Surprising, amyloid was restricted to nonglomerular regions and limited to the renal medulla. This location of apolipoprotein A-I amyloid differs sharply from other systemic amyloidoses that are mainly characterized by glomerular and vascular deposits. The tubulointerstitial nephritis as a result of hereditary apolipoprotein A-I amyloidosis is a rare disease and a challenging diagnosis to recognize. Patients who present with familial tubulointerstitial nephritis associated with liver disease require a high index of suspicion for apolipoprotein A-I amyloidosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16221867     DOI: 10.1681/ASN.2005040382

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  17 in total

1.  [Amyloid diagnostics in rheumatic diseases].

Authors:  C Röcken; J Ernst
Journal:  Pathologe       Date:  2006-11       Impact factor: 1.011

2.  [Amyloidoses in the Berlin Museum of Medical History of the Charité].

Authors:  C Röcken; N Widulin; T Schnalke
Journal:  Pathologe       Date:  2009-05       Impact factor: 1.011

Review 3.  [Amyloid and amyloidoses].

Authors:  C Röcken; M Eriksson
Journal:  Pathologe       Date:  2009-05       Impact factor: 1.011

Review 4.  Pathology and diagnosis of renal non-AL amyloidosis.

Authors:  Sanjeev Sethi; Jason D Theis
Journal:  J Nephrol       Date:  2017-08-21       Impact factor: 3.902

5.  Renal ApoA-1 amyloidosis with Glu34Lys mutation and intra-amyloid lipid accumulation.

Authors:  Nicole K Andeen; Daniel Y Lam; Ian H de Boer; Roberto F Nicosia
Journal:  J Am Soc Nephrol       Date:  2014-06-12       Impact factor: 10.121

6.  Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I.

Authors:  Dorota Rowczenio; Ahmet Dogan; Jason D Theis; Julie A Vrana; Helen J Lachmann; Ashutosh D Wechalekar; Janet A Gilbertson; Toby Hunt; Simon D J Gibbs; Prayman T Sattianayagam; Jenny H Pinney; Philip N Hawkins; Julian D Gillmore
Journal:  Am J Pathol       Date:  2011-08-05       Impact factor: 4.307

7.  Hereditary apolipoprotein AI-associated amyloidosis in surgical pathology specimens: identification of three novel mutations in the APOA1 gene.

Authors:  Magdalena Eriksson; Stefan Schönland; Saniye Yumlu; Ute Hegenbart; Hanna von Hutten; Zarina Gioeva; Peter Lohse; Janine Büttner; Hartmut Schmidt; Christoph Röcken
Journal:  J Mol Diagn       Date:  2009-03-26       Impact factor: 5.568

8.  Three German fibrinogen Aalpha-chain amyloidosis patients with the p.Glu526Val mutation.

Authors:  Magdalena Eriksson; Stefan Schönland; Raoul Bergner; Ute Hegenbart; Peter Lohse; Hartmut Schmidt; Christoph Röcken
Journal:  Virchows Arch       Date:  2008-05-24       Impact factor: 4.064

9.  [Amyloidosis in liver biopsies].

Authors:  Z Gioeva; B Kieninger; C Röcken
Journal:  Pathologe       Date:  2009-05       Impact factor: 1.011

Review 10.  Pathophysiology and treatment of systemic amyloidosis.

Authors:  Julian D Gillmore; Philip N Hawkins
Journal:  Nat Rev Nephrol       Date:  2013-08-27       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.